Trademark Search in Canada

ENIGMA

View On IC.GC.CA

REGISTERED

on 1 Mar 2022

Last Applicant/ Owned by

CANADIAN NEUTRICEUTICAL HEALTH INC.

25 Shepherd Ave w, suite 300Toronto

ONTARIO

M2N6S8

Serial Number

1930751 filed on 15^th Nov 2018

Registration Number

TMA1121252 registered on 1^st Mar 2022

Registration expiry Date

1^st Mar 2032

Correspondent Address

ANITA MAR

dba Trademark AngelSuite 521,6-2557 Dougall Avenue,Windsor,

ONTARIO

N8X1T5

ENIGMA

Trademark usage description

body and beauty care cosmetics, excluding perfumery; cosmetics for personal use, excluding perfumery; makeup; none of the aforesaid goods being or inc Read More

Classification Information

Class [003]
Body and beauty care cosmetics, excluding perfumery; cosmetics for personal use, excluding perfumery; makeup; none of the aforesaid goods being or including perfumery

Classification kind code

Class [005]
Anti-diabetic pharmaceuticals; antidiabetic pharmaceuticals; anti-epileptic pharmaceutical preparations; herbal supplements for the treatment of the respiratory system; herbal supplements for use in dermatology, namely, dermatitis, eczema, psoriasis; injectable pharmaceutical contraceptives; mineral supplements; pharmaceutical hormonal preparations, namely, corticosteroids, hormone replacement therapy preparations, oral contraceptives, thyroid hormone preparations; pharmaceutical preparations for reducing cholesterol; pharmaceutical preparations for regulating the immune system; pharmaceutical preparations for the prevention of osteoporosis; pharmaceutical preparations for the relief of pain; pharmaceutical preparations for the treatment of acne; pharmaceutical preparations for the treatment of allergies; pharmaceutical preparations for the treatment of asthma; pharmaceutical preparations for the treatment of autoimmune diseases; pharmaceutical preparations for the treatment of bacterial skin infections, fungal skin infections, viral skin infections and parasitic skin infections; pharmaceutical preparations for the treatment of blood disorders; pharmaceutical preparations for the treatment of bone diseases; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of cardiovascular diseases; pharmaceutical preparations for the treatment of carpal tunnel syndrome; pharmaceutical preparations for the treatment of chronic pain; pharmaceutical preparations for the treatment of cranial or facial nerve disorders; pharmaceutical preparations for the treatment of degenerative nerve diseases and disorders, namely, Alzheimer's disease, Parkinson's disease, Huntington's disease and multiple sclerosis; pharmaceutical preparations for the treatment of dental and oral diseases; pharmaceutical preparations for the treatment of diabetes; pharmaceutical preparations for the treatment of diseases, disorders and infections of the endocrine system, namely growth and thyroid disorders; pharmaceutical preparations for the treatment of diseases, disorders and infections of the spinal cord systems and related cartilage and tissue; pharmaceutical preparations for the treatment of drug and alcohol abuse; pharmaceutical preparations for the treatment of gastro-intestinal diseases; pharmaceutical preparations for the treatment of genito-urinary and pelvic diseases, disorders and infections, namely infertility, sexually transmitted diseases, incontinence and sexual dysfunction; pharmaceutical preparations for the treatment of genitourinary diseases, namely, urological diseases, infertility, sexually transmitted diseases, inflammatory pelvic diseases; pharmaceutical preparations for the treatment of glaucoma; pharmaceutical preparations for the treatment of gout; pharmaceutical preparations for the treatment of headaches; pharmaceutical preparations for the treatment of heart rhythm disorders; pharmaceutical preparations for the treatment of immunologic diseases, namely, autoimmune diseases, immunologic deficiency syndromes; pharmaceutical preparations for the treatment of infectious diseases, namely respiratory infections, eye infections; pharmaceutical preparations for the treatment of inflammatory connective tissue diseases and injuries; pharmaceutical preparations for the treatment of inflammatory diseases, namely, inflammatory bowel diseases, inflammatory connective tissue diseases; pharmaceutical preparations for the treatment of inflammatory muscle diseases and disorders; pharmaceutical preparations for the treatment of metabolic diseases and disorders, namely diabetes, hypoglycaemia, gout, osteoarthritis, muscular dystrophy, anemia; pharmaceutical preparations for the treatment of migraine; pharmaceutical preparations for the treatment of motion sickness; pharmaceutical preparations for the treatment of multiple sclerosis; pharmaceutical preparations for the treatment of myalgia and neuralgia; pharmaceutical preparations for the treatment of neurological diseases, namely, Alzheimer's, Huntington's Disease, cerebral palsy; pharmaceutical preparations for the treatment of neurological disorders, namely, brain injury, spinal cord injury, seizure disorders; pharmaceutical preparations for the treatment of neuromuscular diseases and disorders, namely, cerebrovascular accident (stroke), Parkinson's disease, multiple sclerosis, myasthenia gravis, Huntington's disease; pharmaceutical preparations for the treatment of oncological diseases and disorders; pharmaceutical preparations for the treatment of ophthalmological diseases and disorders; pharmaceutical preparations for the treatment of physical and psychological addictions, namely, gambling addiction, eating disorders and addictions, nicotine addiction, Internet addiction, drug addiction; pharmaceutical preparations for the treatment of psychiatric and other brain diseases and disorders, namely, anxiety, mood disorders, schizophrenia, cognitive and bipolar disorders, epilepsy, Alzheimer's, cerebral palsy, Parkinson's disease, multiple scle; pharmaceutical preparations for the treatment of psychiatric diseases, namely, mood disorders, anxiety disorders, cognitive disorders, schizophrenia; pharmaceutical preparations for the treatment of varicose veins; pharmaceutical preparations for the treatment of vascular diseases; pharmaceutical preparations for use in gastroenterology; pharmaceutical preparations for use in ocular disorders; pharmaceutical preparations for use in oncology; pharmaceutical preparations for use in ophthalmology; pharmaceutical products for ophthalmological use; mineral supplements; vitamin and mineral dietary supplements; vitamin and mineral food supplements; vitamin and mineral preparations; vitamin and mineral supplements; vitamin supplements;

Classification kind code

Mark Details

Serial Number

1930751

Mark Type

Trademark

Legal History

Action Taken	Status
Submitted for opposition 191 on 24^th Nov 2021	Registration Fee Notice Sent
Submitted for opposition 71 on 22^nd Nov 2021	Opposition Removed
Submitted for opposition 110 on 28^th Sept 2021	Proposed Opposition
Submitted for opposition 42 on 28^th Jul 2021	Advertised
Submitted for opposition 27 on 29^th Jun 2021	Approval Notice Sent
Submitted for opposition 26 on 29^th Jun 2021	Approved
Submitted for opposition 22 on 22^nd Jun 2021	Search Recorded
Submitted for opposition 31 on 20^th Nov 2018	Formalized
Submitted for opposition 1 on 16^th Nov 2018	Created
Submitted for opposition 30 on 15^th Nov 2018	Filed

ENIGMA

Classification Information

Class [003]Body and beauty care cosmetics, excluding perfumery; cosmetics for personal use, excluding perfumery; makeup; none of the aforesaid goods being or including perfumery

Classification kind code

Classification kind code

Mark Details

Serial Number

Mark Type

Legal History

Class [003]
Body and beauty care cosmetics, excluding perfumery; cosmetics for personal use, excluding perfumery; makeup; none of the aforesaid goods being or including perfumery